Top Markets
#1 Talus Network Talus Network +31.64%
#2 Starpower Starpower +31.04%
#3 Brevis Brevis +30.27%
#4 Keep Network Keep Network +29.44%
#5 Tung Tung Tung Sahur Tung Tung Tung Sahur +25.54%
#6 MemeCore MemeCore +24.60%
#7 Infinity Ground Infinity Ground +22.45%
#8 Allora Allora +21.35%
#9 屎壳郎 (Dung Beetle) 屎壳郎 (Dung Beetle) +17.45%
#10 DeepBook DeepBook +17.40%
Coin of the day
Talus Network Talus Network
Instellingen
Taal
DUTCH
Valuta
USD
Thema
IntegraGen SA IntegraGen SA

IntegraGen SA

ALINT
Rang in aandelen #19673
IntegraGen SA provides human genome analysis services for academic researcher... IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
Aandeelprijs
$0.20876331
Marktkapitalisatie
$1.38M
Verandering (1 dag)
1.15%
Verandering (1 jaar)
-64.84%
Land
FR
Handel IntegraGen SA (ALINT)

Categorie

Healthcare
P/B-ratio voor IntegraGen SA (ALINT)
P/B-ratio op July 2026 TTM: -1.30
Volgens de meest recente financiële rapporten en aandelenkoers van IntegraGen SA is de huidige P/B-ratio (TTM) -1.30. Eind 2023 had het bedrijf een P/B-ratio van 2.94.
P/B-ratiohistoriek voor IntegraGen SA van 2008 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) -1.30 -159.89%
2024 2.17 -26.23%
2023 2.94 -19.34%
2022 3.64 8.64%
2021 3.35 -46.52%
2020 6.27 140.19%
2019 2.61 1.67%
2018 2.57 -38.19%
2017 4.16 -68.68%
2016 13.27 71.25%
2015 7.75 10.21%
2014 7.03 -74.31%
2013 27.36 207.50%
2012 8.90 -8.80%
2011 9.76 121.29%
2010 4.41 -79.09%
2009 21.08 15.76%
2008 18.21 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 6.8826 -629.59%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5189 -601.61%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.0637 -258.80%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.5808 -452.48%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.7629 -697.33%
NL